New protein could limit stroke damage | COVID-19's stroke rate | Heart valve specialists raise $20M

The protein was designed to prevent cell death through the disruption of two specific Kv2.1 channels.

The researchers compared hospitalized COVID-19 patients with influenza patients treated in 2018.

Foldax, a Salt Lake City-based healthcare company focused on heart valve technology, has closed a $20 million Series D round of financing.

CMS has proposed expanding its national coverage policy for transcatheter edge-to-edge repair of the mitral valve so that it includes patients with functional mitral regurgitation. 

COVID-19 has disrupted routine cardiovascular care all over the world, with some procedures getting delayed for months and many hospitals reporting a significant drop in myocardial infarction patients.

COVID-19 has the potential to infect cardiac cells, causing changes in their ability to function after just 72 hours. 

Rapid reperfusion is linked to improved survival for STEMI patients, but delayed care is still prevalent. 

It’s cloud software turns preoperative medical images into a 3D “digital twin” of the patient’s heart enabling providers to plan procedures and navigate instruments during surgery.

People have been anticipating the demise of radiologists for years, speculating that AI will soon be interpreting imaging results with the precision of a seasoned veteran.